Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Portal Hypertension Related to Cirrhosis
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically significant portal hypertension (CSPH). Participants will undergo EUS-guided portal pressure measurement before start of Carvedilol en after three months of treatment. EUS-guided measurements will be paired with transjugular hepatic venous pressure gradient (HVPG) measurement as well as non-invasive tests for assessment of portal hypertension.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Procedure: endoscopic ultrasound-guided portal pressure measurement — The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.

Primary Outcomes

  • EUS-guided response assessment to NSBB in the treatment of CSPH. (Three months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-17
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universitaire Ziekenhuizen KU Leuven
Principal Investigators:
  • Schalk van der Merwe, MD, PhD (PRINCIPAL_INVESTIGATOR) - Universitaire Ziekenhuizen KU Leuven
Contact Information
Study Contact:
Emma Vanderschueren, MD
0032 16 345918
emma.vanderschueren@uzleuven.be
Petra Windmolders
003216 347581
petra.windmolders@uzleuven.be
Emma Vanderschueren, MD
000-000-0000
emma.vanderschueren@uzleuven.be
University Hospital Leuven
Interventions
  • Procedure: endoscopic ultrasound-guided portal pressure measurement — The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
Study Locations (1 sites)
University Hospital Leuven, Leuven, Vlaams-Brabant 3000 Belgium
Eligibility Criteria
Inclusion Criteria: * Patients with a clinical and/or pathological diagnosis of compensated cirrhosis. * Patients with suspicion of CSPH and thus indication for NSBB treatment. * Patients not yet on NSBB therapy. * Patients willing and able to undergo repeated HVPG and EUS-guided pressure measurements as per protocol. Exclusion Criteria: General criteria * Patient is \<18 or \>80 years of age * Patient is pregnant, breast-feeding or planning to become pregnant during the course of the study * Patient is unwilling or unable to sign the informed consent * Patients in whom general anesthesia or endoscopic procedures are contraindicated Medical criteria * Patients with cirrhosis and HCC Portopulmonary hypertension Portal or splanchnic venous thrombosis Prior TIPS Prior liver transplantation * Non-cirrhotic portal hypertension or pre-sinusoidal liver disease * Cholestatic liver disease with total bilirubin \>3 mg/dl * Previous total or partial splenectomy * Known infection that is not controlled by medical intervention * Patients with contraindications for non-selective beta-blocker therapy, including but not limited to the following baseline vital signs: Systolic BP \<100 mmHg HR \<50 bpm * Patients with reduced life expectancy described by an ASA score of 4 or 5 * INR \>1.7 or platelet count \<50.000 per mm3 * eGFR \<50 ml/min/1.73m2 (CKD-EPI formula) Anatomical criteria * Anatomical abnormalities that prevent access via EUS-guided puncture to the hepatic vein or intrahepatic portion of the portal vein, including anatomy that predisposes to difficult to reach puncture sites or an inadequate needle angle. * Visualization of ascites interposing the puncture tract on EUS * Diagnosis of portal vein thrombosis during EUS * Evidence of active gastrointestinal bleeding during EUS
Conditions Depression
Phase NA
Enrollment 600
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In a sample of patients already receiving ketamine (or esketamine) treatment as part of their clinical care, this project seeks to test whether we can enhance and/or extend (es)ketamine's rapid effects by introducing helpful information delivered by a computer-based cognitive training protocol. This work could ultimately lead to the ability to treat depression more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Behavioral: Cognitive Training — Sessions of cognitive training exercises (15-20min each) self-administered via a web app
  • Behavioral: Sham Training — Sessions of sham training exercises (15-20min each) self-administered via a web app

Primary Outcomes

  • Montgomery Asberg Depression Rating Scale: During (Es)Ketamine Induction (Trajectories from baseline through end of 'induction phase' treatments (up to max of 12 weeks))
  • Montgomery Asberg Depression Rating Scale: After (Es)Ketamine Induction (Trajectories from final 'induction phase' treatment through 4 weeks post-induction)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-12
Completion: 2029-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Rebecca B Price, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Rebecca B Price, PhD
412-383-2150
ketclinics@pitt.edu
Iya Cooper, B.S.
240-242-7318
ketclinics@pitt.edu
Steven Hamilton, MD
Steven.P.Hamilton@kp.org
Kaiser Foundation Research Institute, a division of Kaiser Foundation Hospitals
Interventions
  • Behavioral: Cognitive Training — Sessions of cognitive training exercises (15-20min each) self-administered via a web app
  • Behavioral: Sham Training — Sessions of sham training exercises (15-20min each) self-administered via a web app
Study Locations (3 sites)
Kaiser Foundation Research Institute, a division of Kaiser Foundation Hospitals, Oakland, California 94612 United States
University of Illinois at Chicago, Chicago, Illinois 60612 United States
Baylor College of Medicine, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. be between the ages of 18 and 80 years 2. score ≥20 on the Montgomery-Asberg Depression Rating Scale (MADRS) 3. per SCID-5-RV interview, meet DSM-5 diagnostic criteria for at least one of the following: Major Depressive Disorder, Bipolar Disorder (I or II), Persistent Depressive Disorder, or Other Specified Depressive or Bipolar Disorder 4. exhibit treatment resistance, defined as: (a) failure to respond to ≥1 adequate trials of an evidence-based treatment for mood disorder \[per the Antidepressant Treatment History Form-Short Form Modified Score Sheet (ATHF-SF-Modified)\] and/or (b) failure to respond to ≥1 adequate mood stabilizer or other evidence-based treatment trials (for bipolar depression patients) and/or (c) a history of intolerance during attempted trials of evidence-based treatments for mood disorders and/or (d) failure to respond to ≥1 prior treatment trials (e.g., medication, psychotherapy) for Post Traumatic Stress Disorder (PTSD) 5. be eligible and clinically enrolled for an upcoming ketamine or esketamine induction series at one of our study clinics according to that clinic's standard intake procedures 6. agree to maintain a stable schedule of concomitant psychiatric medications throughout the ketamine induction phase (minor adjustments to PRN meds and timing of meds are allowable), and for 4 weeks post-induction phase 7. possess a level of judgment and understanding sufficient to agree to all procedures required by the protocol and must sign an informed consent document 8. be willing and able to provide names and contact information for at least 1 additional emergency contact in the patient's proximal geographic area (in addition to the ketamine treatment team at the enrolling site) Exclusion Criteria: 1. Presence of current/acute psychosis, mania, or dementia, or a diagnosis of developmental disorder with significant language and/or intellectual impairment (e.g., autism spectrum disorder) 2. Current/acute suicide risk with intent to act, defined as CSSRS past-week ideation score ≥ 4 among outpatients; patients engaged in residential or inpatient care at the time of enrollment need not meet this CSSRS score criterion, as their current/acute suicide risk is extremely low by virtue of the residential/inpatient, round-the-clock care they are already receiving at time of enrollment 3. Concern for dementia or significant cognitive decline, per interviewer observations and impressions during screening assessments 4. Current pregnancy 5. English reading level \<5th grade as per patient self-report Rationale: to ensure adequate reading comprehension for verbal ASAT/sham stimuli which are presented in English
Conditions Pulmonary Edema, Pneumonia, Atelectasis,...
Phase NA
Enrollment 230
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. While implementation of DDR fixed machines are beginning elsewhere in the US, this trial involves the first applications of an FDA-approved portable DDR machine, for use at the bedside in the ICU. The goal of this clinical trial is to determine the feasibility and safety of portable DDR technology in the ICU, as well as to evaluate the improved clinical diagnostic value of the portable DDR system over current standards of care. Participants will receive one to three sets of DDR images, which will then be compared to their clinical gold standard exams (such as chest x-rays, CTs, or VQ scans) to assess and improve the precision and accuracy of measurements such as diaphragmatic motion, lung movement, and perfusion.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Portable Dynamic Digital Radiography (DDR) — (DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team). If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication.

Primary Outcomes

  • I. Extended clinical trial to study the degree of precision of the Portable DDR technology in assessing the cardiopulmonary functions of diaphragm and lung motion. (Up to 2 months)
  • II. Extended clinical trial to study the degree of precision of the Portable DDR technology in assessing the cardiopulmonary functions of pulmonary blood flow. (Up to 2 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-12
Completion: 2027-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Collaborators: Konica Minolta
Principal Investigators:
  • Gyorgy Frendl, MD PhD (PRINCIPAL_INVESTIGATOR) - Brigham and Women's Hospital
  • Hiroto Hatabu, MD PhD (PRINCIPAL_INVESTIGATOR) - Brigham and Women's Hospital
  • Bruno Madore, PhD (PRINCIPAL_INVESTIGATOR) - Brigham and Women's Hospital
Contact Information
Study Contact:
Gyorgy Frendl, MD PhD
617-732-5910
gfrendl@bwh.harvard.edu
Poorva Bagchee, BS
585-203-2857
pbagchee@bwh.harvard.edu
Gyorgy Frendl, MD, PhD
6177325910
gfrendl@bwh.harvard.edu
Brigham and Women's Hospital
Interventions
  • Diagnostic Test: Portable Dynamic Digital Radiography (DDR) — (DDR imaging has already been described in the arm/group description). Each patient in the study will receive at least one set of DDR images, which consists of one 7-second scan in which the patient breaths normally, and a second 7-second scan in which the patient holds their breath (or for ventilated patients, an inspiratory pause is placed by the care team). If the patient's conditions warrant it, up to two sets of follow-up scans may be acquired. For instance, in a patient with diaphragmatic dysfunction, imaging may be completed pre- and post- diaphragmatic plication.
Study Locations (1 sites)
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: Participants must meet all the following inclusion criteria to participate in this study: * Adults (at least 18 years of age) including both intubated/ventilated and non-intubated patients * Likely to have pathology related to either, abnormal diaphragmatic excursion and lung aeration, pulmonary perfusion, increased lung water content or all the above, as well as for cricopharyngeal dysfunction/swallowing difficulties at risk for aspiration. * The subject or a legally authorized representative has provided written informed consent. Exclusion Criteria: Candidates meeting any of the exclusion criteria at baseline will be excluded from study participation. These criteria are: * Special populations, including women with known pregnancy, prisoners, or institutionalized individuals * Patients where additional radiation is clinically contraindicated * Care team does not provide assent for approaching patient/surrogate * For women of child-bearing potential, defined as premenopausal women, a pregnancy test will be administered to determine pregnancy status and confirm eligibility for the study. A pregnancy test will NOT be administered to women who are post-menopausal or have documentation of surgical sterilization.
Conditions Hypertension, Pre Diabetes
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects of taking 150mg of MegaNatural BP GSE per day on blood pressure levels along with influences on heart health through assessing the function of the blood vessel lining and levels of inflammation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: MegaNatural-BP SR 150Mg Tablet — GSE MegaNatural BP
  • Other: Placebo Capsule — given in place of GSE MegaNatural BP

Primary Outcomes

  • Difference in change of systolic blood pressure (6 weeks)
  • Difference in change of diastolic blood pressure (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-08
Completion: 2027-12-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology
Principal Investigators:
  • Britt Burton-Freeman (PRINCIPAL_INVESTIGATOR) - 708-563-8276
Contact Information
Study Contact:
Indika Edirisinghe
708-563-8178
iedirisi@iit.edu
freemanstudies
312-567-5300
freemanstudies@iit.edu
Clinical Nutrition Research Center
Interventions
  • Dietary Supplement: MegaNatural-BP SR 150Mg Tablet — GSE MegaNatural BP
  • Other: Placebo Capsule — given in place of GSE MegaNatural BP
Study Locations (1 sites)
Clinical Nutrition Research Center, Chicago, Illinois 60616 United States
Eligibility Criteria
Inclusion Criteria: * 40-60 years of age * BMI \< 30kg/m2 * elevated blood pressure 120-140 mmHg (systolic) / \<90 mmHg (diastolic) at screening visit * Has fasting blood glucose concentration between 100-125 mg/dL or HbA1c 5.7-6.4%. * Not taking any medications that would interfere with outcomes of the study, i.e. blood pressure lowering medications or anti-diabetes medications. * Able to provide informed consent * Able to comply and perform the procedures requested by the protocol (including dietary restrictions, consumption of study foods, records of food diary and GI tolerance questionnaire, sample collection procedures and study visit schedule) * Able to maintain usual physical activity pattern * Able to avoid / abstain from alcohol and vigorous physical activity for 24 hours prior to and during study visit Exclusion Criteria: * Men and women with known or suspected intolerance, allergies or hypersensitivity to study foods or interventions * Men and women with diabetes or have documented liver, kidney, cardiac, gastrointestinal, metabolic or respiratory diseases. * Men and women with documented physical or mental disease/condition or major surgery as revealed by history or physical examination, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results. * Women who are known to be pregnant or who are intending to become pregnant over the course of the study * Women who are lactating * Taking medication or dietary supplements that may interfere with the outcomes of the study; This may include anti-inflammatory medication (ibuprofen, Aleve/naproxen, aspirin, etc.) * Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI. * Has used antibiotics within the previous 2 months * Had colonoscopy within 3 months * History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional * Substance (alcohol or drug) abuse within the last 2 years * Excessive coffee and tea consumers (\> 4 cups/d) * Donated blood within last 3 months * Men and women who do excessive exercise regularly or are an athlete * Unstable weight: gained or lost weight +/- 5 kg (11 lbs) in previous 2 months * Women who are taking unstable dose and brand of hormonal contraceptives and/or stable dose and brand less than 6 months * Unusual working hours i.e., working overnight (e.g. 3rd shift) * Follows a vegan diet or any extreme dietary patterns
Conditions Bronchopulmonary Dysplasia, Pulmonary Hy...
Phase NA
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In preterm infants \< 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and improve oxygenation. This study may emphasize using point-of-care echocardiography along with electrical impedance tomography (EIT) to optimize ventilator settings in preterm infants. Infants will be randomized to a 4-hour crossover period of increasing and decreasing PEEP in random order from baseline to determine compliance, oxygenation, and cardiac hemodynamics at each step using echocardiography (ECHO) and EIT measurements. There will be a 15-minute washout period after changes prior to data collection.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Increase in the PEEP followed by decrease in the PEEP — Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
  • Other: Decrease in the PEEP followed by increase in the PEEP — Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics

Primary Outcomes

  • Change in cardiac index with increase/decrease in PEEP as measured by ECHO and EIT (During a 4 hour cross-over period on either intervention)
  • PEEP of best compliance and best oxygenation as per EIT measurements (During a 4 hour cross-over period on either intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-01
Completion: 2027-06-30
Eligibility
Age: 7 Days and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Principal Investigators:
  • Kulsajan S Bhatia, MD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
  • Colm P Travers, MD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Kulsajan S Bhatia, MD
9172149882
ksbhatia@uabmc.edu
Colm P Travers, MD
cptravers@uabmc.edu
Interventions
  • Other: Increase in the PEEP followed by decrease in the PEEP — Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
  • Other: Decrease in the PEEP followed by increase in the PEEP — Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
Study Locations (1 sites)
Univerisity of Alabama, Birmingham, Alabama 35233 United States
Eligibility Criteria
Inclusion Criteria: Preterm infants with recovering respiratory distress syndrome (RDS) who were born at a gestational age \< 34 weeks and are receiving respiratory support via conventional mechanical ventilation or on HFJV. * Post-natal age \> 7 days and less than 1 month (outside golden week protocol) * Gestational age ≥ 21 weeks and ≤ 34 week * Infants with written informed consent obtained from legal guardian Exclusion Criteria: * Blood culture-positive sepsis * Congenital anomalies affecting respiration * Cyanotic or ductal-dependent congenital heart disease * Newborns who are considered too unstable for study enrolment per neonatology attending * Newborns on pressors or steroids for maintaining cardiac output * Non-invasive ventilation or newborn with significant BPD (bronchopulmonary dysplasia) with pulmonary hypertension (HTN) * Open skin wounds or abrasions on the chest wall.
Conditions Breast Cancer
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The efficacy of electrosurgical bipolar systems in axillary lymph node dissection for breast cancer surgery is well known. In this study, the investigators aim to determine whether using electrosurgical bipolar systems helps reduce seroma formation in high-risk patients undergoing sentinel lymph node biopsy (SLNB) for breast cancer surgery. The investigators will focus on patients who are expected to experience high drainage output after SLNB, especially those who are obese (BMI\>25) or have undergone preoperative chemotherapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Electrosurgical bipolar system (LigaSure) — Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.

Primary Outcomes

  • Drainage amount (Up to four weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-07
Completion: 2027-04-07
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SMG-SNU Boramae Medical Center
Principal Investigators:
  • Jong-Ho Cheun, M.S. (PRINCIPAL_INVESTIGATOR) - SMG-SNU Boramae Medical Center
Contact Information
Study Contact:
Jong-Ho Cheun, M.S.
+82-10-8754-3054
chun89aaa@naver.com
Jong-Ho Cheun, M.S.
+82-10-8754-3054
chun89aaa@naver.com
SMG-SNU Boramae medical center
Interventions
  • Device: Electrosurgical bipolar system (LigaSure) — Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
Study Locations (1 sites)
SMG-SNU Boramae medical center, Seoul, Dongjak-gu 07061 South Korea
Eligibility Criteria
Inclusion Criteria: * Women aged 20-80 * Candidates for breast-conserving surgery and axillary sentinel lymph node biopsy * BMI over 25 or those who have received preoperative chemotherapy * Overall performance status of Eastern Cooperative Oncology Group (ECOG) 0-2 * Participants who understand the study contents and can provide written consent * Participants without evidence of distant metastasis Exclusion Criteria: * Those with suspected axillary lymph node enlargement or metastasis on preoperative imaging (breast MRI, chest CT, breast ultrasound) * Among patients who had confirmed lymph node metastasis before neoadjuvant chemotherapy, whose preopreative image showed residual disease at axillary lymph node * Those planning for mastectomy * Those planning for axillary lymph node dissection without SLNBx * Male breast cancer patients * Patients with bilateral breast cancer * Illiterate individuals, foreigners, or others who cannot read or understand the consent form * Individuals who voluntarily decide not to participate in the study or do not sign the consent form * Those judged by the researcher to be inappropriate for participation in this study * Study participants who did not have a drain inserted in the surgical area * If the randomized device is not used due to surgical room conditions (e.g., unavailability due to other emergency surgeries, device malfunction) and another device is substituted
Conditions Insomnia, Secondary, Post-stroke Depress...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if Auricular acupuncture works to treat Insomnia Post-stroke patients. It will also learn about the safety of Auricular. The main questions it aims to answer are: * Does Auricular acupuncture reduce the time it took participants to fall asleep? * Dose Auricular acupuncture increase the number of hours participants slept? * Dose Auricular acupuncture improve sleep quality as measured by The Pittsburgh Sleep Quality Index (PSQI)? * What medical problems do participants have when taking Auricular acupuncture? Researchers will compare Auricular acupuncture to a sham Auricular acupuncture (a look-alike acupuncture needles that contains no needles) to see if Auricular acupuncture works to treat insomnia post-stroke. Participants will: * Take Auricular acupuncture or sham Auricular acupuncture every 5 days for 4 weeks. * Checkups and evaluate sleep onset time, sleep hours, and sleep quality every 5 days for 4 weeks. * Keep a diary sleep of their symptoms and the number of times they use sleeping pills.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Other: Auricular Acupuncture needles — Auricular Acupuncture needles 5 days in 2 weeks
  • Other: Sham Auricular Acupuncture needles — Sham Auricular Acupuncture needles 5 days in 2 weeks

Primary Outcomes

  • Change sleep quality as measured by The Pittsburgh Sleep Quality Index (PSQI) (Baseline and Week 4)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-01
Completion: 2024-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City
Contact Information
Study Contact:
An Thi Thuy Nguyen
0773030312
nguyenan27011997@gmail.com
Interventions
  • Other: Auricular Acupuncture needles — Auricular Acupuncture needles 5 days in 2 weeks
  • Other: Sham Auricular Acupuncture needles — Sham Auricular Acupuncture needles 5 days in 2 weeks
Study Locations (1 sites)
HoChiMinh University of Medicine and Phamacy, Ho Chi Minh City, Vietnam
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older, with a post-stroke period of 03 months or more, based on discharge papers or medical records. * Patients who meet the diagnostic criteria for insomnia according to the DSM-V of the American Psychiatric Association for at least 3 months. Exclusion Criteria: * Patients with insomnia before the stroke. * Patients diagnosed with other sleep disorders such as sleep apnea syndrome, narcolepsy. * Patients diagnosed with neurological diseases or psychiatric disorders such as: Anxiety disorders, autism spectrum disorders, depression, obsessive-compulsive disorder, behavioral disorders affecting sleep before the stroke. * Patients are using antidepressants, psychiatric drugs. * Patients participating in other clinical trials with behavioral, psychological or complementary medical interventions during the study period. * Patients not cooperating during data collection
Conditions Anatomic Stage III Breast Cancer AJCC v8...
Phase PHASE2
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that has spread to nearby tissue or lymph nodes (locally advanced) and is unable to be operated on (inoperable). Tamoxifen works by blocking the effects of estrogen in the breast. This may help stop the growth of tumor cells that need estrogen to grow. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving tamoxifen and pegylated liposomal doxorubicin together may work better in treating patients with metastatic or inoperable, locally advanced triple negative breast cancer than giving either of these drugs alone.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biopsy — Undergo tumor biopsy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Computed Tomography — Undergo CT scan
  • Procedure: Echocardiography — Undergo echocardiography
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Drug: Pegylated Liposomal Doxorubicin Hydrochloride — Given IV
  • Drug: Tamoxifen — Given PO

Primary Outcomes

  • Overall response rate (Up to 4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-03
Completion: 2028-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Roswell Park Cancer Institute
Principal Investigators:
  • Sheheryar Kabraji (PRINCIPAL_INVESTIGATOR) - Roswell Park Cancer Institute
Contact Information
Study Contact:
Sheheryar Kabraji
716-845-3429
Sheheryar.Kabraji@roswellpark.org
Roswell Park Cancer Institute
Sheheryar Kabraji
Roswell Park Cancer Institute
Interventions
  • Procedure: Biopsy — Undergo tumor biopsy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Computed Tomography — Undergo CT scan
  • Procedure: Echocardiography — Undergo echocardiography
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
Study Locations (1 sites)
Roswell Park Cancer Institute, Buffalo, New York 14263 United States
Eligibility Criteria
Inclusion Criteria: * Patients with pathologically confirmed metastatic triple negative breast cancer (ER ≤ 10%) that have been previously treated with at least 2 lines of therapy in the metastatic setting * Patients must have a confirmed eligible TP53 genomic alteration, as determined by the Roswell Park Oncomine™ Precision Assay (OPA) or similar CLIA-approved assay, using either an archival metastatic tumor sample or, if unavailable, a fresh biopsy. Uncertainty about the eligibility of the TP53 genomic alteration for this study can be resolved by discussion with the study PI * Patients must have ERα (estrogen receptor alpha) and PgR (progesterone receptor) status assessed using current American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines. Patients are eligible if the tumor staining is ERα low/negative (ER ≤ 10%) and PgR negative by ASCO/CAP guidelines * The tumor must be HER-2 negative by immunochemistry (IHC) 0-1+ or IHC 2 + and fluorescence in situ hybridization (FISH) negative * Patients must be ≥ 18 years of age * Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Absolute neutrophil count (ANC) ≥ 1500/ μL * Hemoglobulin (hb) ≥ 9 g/dL * Platelet count ≥ 100,000/ μL * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2 x ULN * Creatinine clearance \> 60 mL/min (Cockroft-Gault Equation) * Left ventricular ejection fraction (LVEF) assessment must be performed within 30 days prior to enrollment. (LVEF assessment performed by 2-D echocardiogram is preferred; however, multigated acquisition scan \[MUGA\] scan may be substituted based on institutional preferences). The LVEF must be ≥ 50% regardless of the cardiac imaging facility's lower limit of normal * Patients must be able to swallow oral medications * Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: * Patients must not have any known contraindications to endocrine therapy, in the opinion of the treating investigator * Participants who have had chemotherapy, hormonal/endocrine therapy, immunotherapy, biologics or radiotherapy (as well as any other investigational agents/devices) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to Cycle 1 Day 1 (6 weeks for nitrosoureas or mitomycin C), or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Have a known history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to tamoxifen or any of its excipients * Patients known or suspected to have hypercoagulable syndrome or with history of venous or arterial thrombosis, stroke, transient ischemic attack (TIA), or pulmonary embolism * Known human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS) related illness * Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimen. This includes angina pectoris, arrhythmias except for benign premature ventricular contractions, a history of myocardial infarction, documented congestive heart failure (CHF) or cardiomyopathy * Patients with cirrhosis or severe hepatic impairment * Patients must not have a condition or an uncontrolled intercurrent illness including, but not limited to any of the following: ongoing or active infection requiring systemic treatment, except uncomplicated urinary tract infection (UTI), or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or nursing female participants * Unwilling or unable to follow protocol requirements * Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE1, PHASE2
Enrollment 22
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies how well fluorine F 18 fluorthanatrace (\[18F\]FTT) positron emission tomography (PET) works in imaging patients with breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) who are receiving standard of care (SOC) poly (ADP-ribose) polymerase (PARP) inhibitors with or without immune checkpoint inhibitors (ICI) to be able to detect clinical response to PARP inhibitor ± ICI treatment. \[18F\]FTT is a radiotracer that targets and binds to PARP1 which can potentially be used for the imaging of PARP1 expression using PET. Once administered, \[18F\]FTT targets and binds to PARP1. Upon PET, PARP1-expressing tumor cells can be visualized. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case, \[18F\]FTT. Because some cancers take up \[18F\]FTT it can be seen with PET. PARP inhibitors work as a targeted therapy by blocking an enzyme involved in repairing cell damage. It may cause tumor cells to die. ICI may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Combining \[18F\]FTT with a PET scan may help detect tumor cells better in patients with metastatic breast cancer who are receiving standard of care PARP inhibitors with our without ICI treatment.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: Best Practice — Receive of standard care
  • Procedure: Biopsy of Breast — Undergo breast biopsy
  • Procedure: Computed Tomography — Undergo FDG PET/CT
  • Other: Electronic Health Record Review — Ancillary studies
  • Other: Fludeoxyglucose F-18 — Given FDG
  • Radiation: Fluorine F 18 Fluorthanatrace — Given IV
  • Drug: Immune Checkpoint Inhibitor — Receive ICI treatment
  • Drug: Poly (ADP-Ribose) Polymerase Inhibitor — Receive PARP inhibitor treatment

Primary Outcomes

  • Overall response rate (ORR) (Baseline up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-02-26
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 22 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Collaborators: Breast Cancer Research Foundation
Principal Investigators:
  • Jennifer Specht, MD (PRINCIPAL_INVESTIGATOR) - Fred Hutch/University of Washington Cancer Consortium
Contact Information
Study Contact:
Jennifer Specht, MD
206-606-6889
jspecht@uw.edu
Jennifer Specht, MD
206-606-6889
jspecht@uw.edu
Fred Hutch/University of Washington Cancer Consortium
Jennifer Specht, MD
Fred Hutch/University of Washington Cancer Consortium
Interventions
  • Other: Best Practice — Receive of standard care
  • Procedure: Biopsy of Breast — Undergo breast biopsy
  • Procedure: Computed Tomography — Undergo FDG PET/CT
  • Other: Electronic Health Record Review — Ancillary studies
  • Other: Fludeoxyglucose F-18 — Given FDG
Study Locations (1 sites)
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States
Eligibility Criteria
Inclusion Criteria: * Patients must have histologically confirmed invasive breast cancer with metastatic disease * Patients must be candidates for treatment with PARP inhibitor as a single agent or for PARP inhibitor in combination with an ICI per treating physician discretion * Patients must have evaluable disease or at least one measurable lesion that can be assessed at baseline by CT (or magnetic resonance imaging \[MRI\]) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Age \>= 18 years * Karnofsky performance status (KPS) \>= 50% or Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Archival tissue (formalin-fixed paraffin-embedded \[FFPE\]) from at least one metastatic site biopsy should be available prior to study enrollment; if archival tissue is not available, then a metastatic site biopsy will be required during the study screening period * Patient must be willing to proceed with an on-treatment biopsy of metastatic site if an on-treatment \[18F\]FTT PET will be performed (at 12 ± 4 weeks after starting PARP inhibitor ± ICI treatment) * For women of childbearing potential, a negative serum pregnancy test is required within 7 days prior to \[18F\]FTT PET imaging on day 1. For women who obtain on-treatment (12-week) \[18F\]FTT imaging, a negative serum pregnancy test will be required within 7 days prior to \[18F\]FTT PET imaging * Men and women of reproductive potential need to agree to employ two highly effective and acceptable forms of contraception throughout their participation in the study * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations * Ability to understand and the willingness to sign a written informed consent document. Informed consent must be provided prior to any study specific procedures Exclusion Criteria: * Patients with prior myelodysplastic syndrome or acute myeloid leukemia due to rare risk associated with PARP inhibitor therapy * Pregnant or breastfeeding women * Patient with a known hypersensitivity to the proposed PARP inhibitor product * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of PARP inhibitor therapy (per investigator's discretion)
Conditions Estrogen Receptor-Positive Breast Carcin...
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Coriolus Versicolor Extract — Dietary Supplement Given PO
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Change in Ki-67 (Baseline; at the time of surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-25
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Brenda J. Ernst, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Cancer Center Clinical Trials
507-293-6386
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Arizona
Interventions
  • Drug: Coriolus Versicolor Extract — Dietary Supplement Given PO
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (1 sites)
Mayo Clinic in Arizona, Scottsdale, Arizona 85259 United States
Eligibility Criteria
Inclusion Criteria: * Women ≥ 18 years of age * Histological confirmation of ER+, HER2- breast cancer, newly diagnosed and tissue available for central confirmation of Ki-67 measurement. Subjects are eligible if they have a Ki-67 of ≥10%. Ki-67 will be repeated for patients who have had this done externally. * Scheduled for definitive breast surgery * Detectable disease as defined by mammography, breast ultrasound of greater than 5mm in size. * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible * Post menopausal as defined by: * Self-reported last menstrual period greater than 12 months, or * Bilateral oophorectomy, or * Follicle stimulating hormone (FSH) \>20 mIU/mL, and estradiol level ≤ 20 pg/mL * Not taking aromatase inhibitor or a selective estrogen receptor modifier * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 obtained ≤ 90 days prior to registration * Platelet count ≥ 100,000/mm\^3 (obtained ≤ 90 days prior to registration) * Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (obtained ≤ 90 days prior to registration) * Hemoglobin ≥ 11 g/dL (obtained ≤ 90 days prior to registration) * Serum transaminase \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\] ≤ 1.2 x upper limit of normal (ULN) (obtained ≤ 90 days prior to registration) * Alkaline phosphatase ≤ 1.2 x ULN (obtained ≤ 90 days prior to registration) * Serum creatinine ≤ 1.2 x ULN (obtained ≤ 90 days prior to registration) * Provide written informed consent * Ability to complete the Symptom Experience Diary by themselves or with assistance Exclusion Criteria: * Ki-67 of \<10% * Current use of any medicinal mushrooms * Patient with locally advanced cancer who will require neoadjuvant therapy or metastatic cancer * Currently on systemic chemotherapy * Concurrent endocrine therapy (selective estrogen receptor modifiers or aromatase inhibitors) * Allergy to mushrooms * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Immunocompromised patients * Patients known to be HIV positive and currently receiving antiretroviral therapy. * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial * Uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Or psychiatric illness/social situations that would limit compliance with study requirements * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Other active malignancy 3 years prior to registration * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix * NOTE: If there is a history of prior malignancy, they must not be receiving chemotherapy treatment for their cancer

PILI 'Āina Household

NCT06526273
Recruiting
Conditions Type 2 Diabetes, Hypertension, Dyslipide...
Phase NA
Enrollment 210
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Native Hawaiians' traditional lifestyles and diets ensured the mutual health and well-being of the land and its inhabitants, which stand in stark contrast to the disproportionately high prevalence of diet-related, cardiometabolic diseases they experience today. In this project, the investigators will adapt and test an evidence-based multilevel intervention entitled PILI 'Āina to improve the self-management of prevalent cardiometabolic diseases and reduce risk factors for developing new diet-related illnesses and implement and evaluate the impact and sustainability of community-wide cooking demonstrations. The objectives of this project are to optimize the effectiveness and sustainability of PILI 'Āina, improve diet quality, cardiometabolic markers, promote traditional Native Hawaiian diets, and improve social cohesion.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: PILI 'Āina — Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker. At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks).
  • Other: Control — Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker based on previously tested materials and protocols. At 3 months, participants randomized to the control group will receive monthly untailored health education information and links to community resources from the community health worker via United States Postal Service or electronic messaging. Examples include information on food assistance programs, farmers' markets, cultural events, and physical activity events.

Primary Outcomes

  • Diet Quality (Baseline, 3 month, 9 month, 12 month)
  • Weight (Baseline, 3 month, 9 month, 12 month)
  • Height (Baseline, 3 month, 9 month, 12 month)
  • Blood pressure (Baseline, 3 month, 9 month, 12 month)
  • hemoglobin A1c (Baseline, 3 month, 9 month, 12 month)
  • Lipids (Baseline, 3 month, 9 month, 12 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-12
Completion: 2029-02-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 210 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Hawaii
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Claire Ing, DrPH (PRINCIPAL_INVESTIGATOR) - University of Hawaii
Contact Information
Study Contact:
Claire Ing, DrPH
808-692-1042
clairemt@hawaii.edu
Ki'i Aweau
808-220-2110‬
kkaweau@hawaii.edu
Adrienne Y Dillard, PhD
(808) 520-8997
kula.papakolea@gmail.com
Kula no nā Po'e Hawai'i
Interventions
  • Behavioral: PILI 'Āina — Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker. At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks).
  • Other: Control — Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker based on previously tested materials and protocols. At 3 months, participants randomized to the control group will receive monthly untailored health education information and links to community resources from the community health worker via United States Postal Service or electronic messaging. Examples include information on food assistance programs, farmers' markets, cultural events, and physical activity events.
Study Locations (2 sites)
Kula no nā Po'e Hawai'i, Honolulu, Hawaii 96813 United States
Kapolei Community Development Corporation, Kapolei, Hawaii 96707 United States
Eligibility Criteria
Inclusion Criteria: * Age 18+ (looking for older adults) * Native Hawaiian resident in a participating homestead * Overweight or obese (BMI ≥ 25 kg/m\^2) * Prior diagnosis of T2D or pre-diabetes, hypertension, and/or dyslipidemia (LDL cholesterol ≥ 130 mg/dL) * Capable of 150 minutes of moderate physical activity (e.g., brisk walking) per week * Willing and able to participate in all aspects of the individual and household-level intervention * Fluent in written and spoken English Exclusion Criteria: * No children * Pregnancy * Serious illness such as cancer or chronic pain that may contraindicate full participation
Conditions Hypertension
Phase NA
Enrollment 364
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether patients assigned to the telemedicine (HealthCap) group demonstrate non-inferior blood pressure (BP) control compared to patients in the usual care group at 12 months. The main question it aims to answer is: * Do participants in telemedicine group have non-inferior daytime ambulatory blood pressure readings at 12-month, compared to usual care group? * Do participants in telemedicine group have better HT treatment, higher self-efficacy, reduced number of visits to primary care clinics and similar health care utilisation other than GOPCs, compared to usual care group? Participant in telemedicine group will: * Receive reminders to measure 7-day home blood pressure before their index consultation. * Get their drug refilled automatically as well as have consultations deferred 16-18 weeks later, if their blood pressure is under optimal control. * Have consultations as scheduled, if their BP is suboptimal or any of the safety questions screen positive. Participants in control group will: * Have consultation with physicians every 16-18 weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Telemedicine — a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
  • Other: Usual care — Participants will be followed up as usual by face-to-face consultation with the doctors

Primary Outcomes

  • daytime systolic blood pressure (from the enrollment at 12-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-01
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 364 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Contact Information
Study Contact:
Kam Pui Lee
+85222528462
lkp032@cuhk.edu.hk
Eric Kam-Pui Lee, MSc
22528462
lkp032@cuhk.edu.hk
HKW and NTEC GOPC
Interventions
  • Device: Telemedicine — a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
  • Other: Usual care — Participants will be followed up as usual by face-to-face consultation with the doctors
Study Locations (1 sites)
HKW and NTEC GOPC, Hong Kong, Hong Kong Hong Kong
Eligibility Criteria
Inclusion Criteria: * (i) having a diagnosis of essential HT; * (ii) on anti-HT medications; * (iii) well-controlled HT on out-of-office BP measurements, including HBPM or ambulatory blood pressure measurements (ABPM) (measurement algorithm and details under methods). ABPM or HBPM are preferred to office BP due to their superior reproducibility and predictivity to cardiovascular outcomes. Furthermore, office BP misclassifies 30-40% of patients as having suboptimal BP control due to white-coat effect. From our pilot study, some patients with optimal BP are reluctant to undergo ABPM before recruitment into the RCT, and HBPM is more acceptable to these patients and is therefore included. According to local and international guidelines, optimal out-of-office daytime BP should be \&lt;135/85 mmHg for patients without comorbidities and \&lt;130/85 mmHg for patients with comorbidities that increase cardiovascular risk (i.e. stroke, ischaemic heart diseases, heart failure, diabetes mellitus (DM), and chronic kidney diseases) respectively; * (iv) can read basic Chinese (language used in the HealthCap); * (v) have used any mobile app (not HT-related) in the previous 1 year; and * (vii) aged between 18-80. Exclusion Criteria: * (i) cannot provide informed consent; * (ii) unwillingness to conduct HBPM or repeated ABPM; * (iii) relative contraindications to ABPM (i.e., diagnosed atrial fibrillation, nighttime workers, occupational drivers, or patients with bleeding tendencies); * (iv) have severe mental illnesses that impair their ability to use HealthCap, including those diagnosed with schizophrenia, dementia, or as being actively suicidal; * (v) a diagnosis of other acute or chronic diseases that need regular physical assessments and/or medication changes (e.g., suboptimally controlled DM \[e.g., glycosylated haemoglobin (HbA1c)≥7%\], depression requiring medications, active cancer); and (vi) predicted lifespan of \&lt;1 year.